Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
Indexado
WoS WOS:001240518700001
Scopus SCOPUS_ID:85181843481
DOI 10.1016/J.JTHO.2023.10.012
Año 2024
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Introduction: The accurate assessment of nodal (N) status is crucial to the management and prognostication of nonmetastatic NSCLC. We sought to determine whether the current N descriptors should be maintained or revised for the upcoming ninth edition of the international TNM lung cancer staging system. Methods: Data were assembled by the International Association for the Study of Lung Cancer on patients with NSCLC, detailing both clinical and pathologic N status, with information about anatomical location and individual station-level identification. Survival was calculated by the Kaplan-Meier method and prognostic groups were assessed by a Cox regression analysis. Results: Data for clinical N and pathologic N status were available in 45,032 and 35,009 patients, respectively. The current N0 to N3 descriptors for both clinical N and pathologic N categories reflect prognostically distinct groups. Furthermore, single-station N2 involvement (N2a) exhibited a better prognosis than multistation N2 involvement (N2b) in both clinical and pathologic classifications, and the differences between all neighboring nodal subcategories were highly significant. The prognostic differences between N2a and N2b were robust and consistent across resection status, histologic type, T category, and geographic region. Conclusions: The current N descriptors should be maintained, with the addition of new subdescriptors to N2 for single-station involvement (N2a) and multiple-station involvement (N2b).

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Respiratory System
Oncology
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Huang, James Hombre Memorial Sloan-Kettering Cancer Center - Estados Unidos
Mem Sloan Kettering Canc Ctr - Estados Unidos
2 Osarogiagbon, Raymond U. - Baptist Cancer Center - Estados Unidos
Baptist Canc Ctr - Estados Unidos
3 Giroux, Dorothy J. Mujer Fred Hutchinson Cancer Center - Estados Unidos
Canc Res & Biostat - Estados Unidos
4 Nishimura, Katherine K. Mujer Fred Hutchinson Cancer Center - Estados Unidos
Canc Res & Biostat - Estados Unidos
5 Bille, Andrea Mujer Guy's Hospital - Reino Unido
King's College London - Reino Unido
Guys Hosp - Reino Unido
Kings Coll Univ - Reino Unido
6 Cardillo, Giuseppe Hombre Azienda Ospedaliera San Camillo Forlanini - Italia
UniCamillus - Saint Camillus International University of Health and Medical Sciences - Italia
Azienda Osped San Camillo Forlanini - Italia
UniCamillus St Camillus Int Univ Hlth Sci - Italia
7 Detterbeck, Frank Hombre Yale School of Medicine - Estados Unidos
YALE UNIV - Estados Unidos
8 Kernstine, Kemp - UT Southwestern Medical School - Estados Unidos
Univ Texas Southwestern Med Ctr - Estados Unidos
9 Kim, Hong Kwan - Samsung Medical Center, Sungkyunkwan University - Corea del Sur
Sungkyunkwan Univ - Corea del Sur
10 Lievens, Yolande Mujer Universitair Ziekenhuis Gent - Bélgica
Ghent Univ Hosp - Bélgica
Univ Ghent - Bélgica
11 Lim, Eric Hombre Imperial College London - Reino Unido
Royal Brompton Hospital - Reino Unido
Imperial Coll London - Reino Unido
Royal Brompton Hosp - Reino Unido
12 Marom, Edith - Tel Aviv University - Israel
Tel Aviv Univ - Israel
13 Prosch, Helmut Hombre Allgemeines KrankenHaus Wien - Austria
Med Univ Vienna - Austria
14 Putora, Paul Martin Hombre Kantonsspital St.Gallen - Suiza
University of Bern - Suiza
Kantonsspital St Gallen - Suiza
Univ Bern - Suiza
15 Rami-Porta, Ramon Hombre Hospital Universitari de Bellvitge - España
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias - España
Univ Barcelona - España
Network Ctr Biomed Res Resp Dis CIBERES Lung Canc - España
16 Rice, David - University of Texas Health Science Center at Houston - Estados Unidos
Univ Texas MD Anderson Canc Ctr - Estados Unidos
17 Rocco, Gaetano Hombre Memorial Sloan-Kettering Cancer Center - Estados Unidos
Mem Sloan Kettering Canc Ctr - Estados Unidos
18 Rusch, Valerie W. Mujer Memorial Sloan-Kettering Cancer Center - Estados Unidos
Mem Sloan Kettering Canc Ctr - Estados Unidos
19 Opitz, Isabelle - UniversitatsSpital Zurich - Suiza
Univ Hosp Zurich - Suiza
20 Vasquez, Francisco Suarez - Universidad de Los Andes, Chile - Chile
21 Van Schil, Paul Hombre Universitair Ziekenhuis Antwerpen - Bélgica
Antwerp Univ - Bélgica
Universitair Ziekenhuis Gent - Bélgica
22 Jeffrey Yang, Chi Fu - Massachusetts General Hospital - Estados Unidos
22 Yang, Chi-Fu Jeffrey - MASSACHUSETTS GEN HOSP - Estados Unidos
23 Asamura, Hisao Hombre Keio University School of Medicine - Japón
Keio Univ - Japón
24 Staging Prognostic Factors Comm Corporación
25 Advisory Boards Corporación
26 Participating Inst Lung Canc Domai Corporación

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
National Institutes of Health
Bristol-Myers Squibb
National Cancer Institute
Medtronic
AstraZeneca
Boehringer Ingelheim
Merck Sharp Dohme
Janssen
Siemens
Roche
Arthrex GmbH
Cancer Research United Kingdom
Bristol Myers Squibb Merck Sharp Dohme

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
∗ CRISP is an AIO study (project no. AIO TRK-0315) under the medical leadership of the Executive Committee (Prof. F. Griesinger (Oldenburg), Prof. M. Thomas (Heidelberg), Dr. M. Sebastian (Frankfurt) and Dr. W. Eberhardt (Essen)). CRISP is conducted by AIO-Studien-gGmbH (sponsor) in cooperation with iOMEDICO (conception, project management, analysis). CRISP is supported by AstraZeneca GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol Myers Squibb GmbH & Co. KGaA, Celgene GmbH, Lilly Deutschland GmbH, Merck Sharp & Dohme Sharp & Dohme GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, Roche Pharma AG and Takeda Pharma Vertrieb GmbH & Co. KG. However, these companies have no input into or influence over data analysis, data interpretation, or writing of the manuscript.
∗ CRISP is an AIO study (project no. AIO TRK-0315) under the medical leadership of the Executive Committee (Prof. F. Griesinger (Oldenburg), Prof. M. Thomas (Heidelberg), Dr. M. Sebastian (Frankfurt) and Dr. W. Eberhardt (Essen)). CRISP is conducted by AIO-Studien-gGmbH (sponsor) in cooperation with iOMEDICO (conception, project management, analysis). CRISP is supported by AstraZeneca GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol Myers Squibb GmbH & Co. KGaA, Celgene GmbH, Lilly Deutschland GmbH, Merck Sharp & Dohme Sharp & Dohme GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, Roche Pharma AG and Takeda Pharma Vertrieb GmbH & Co. KG. However, these companies have no input into or influence over data analysis, data interpretation, or writing of the manuscript.
Disclosure: Dr. Huang reports receiving grants from the National In-stitutes of Health/National Cancer Institute (NIH/NCI) Cancer Center Support Grant during the conduct of the study. Dr. Osarogiagbon re-ports receiving grants and personal fees from the NCI during the conduct of the study; personal fees from American Cancer Society, Biodesix, Genentech/Roche, LUNGevity Foundation, Tryptych Health-care Partners, AstraZeneca, GE Healthcare, Eli Lilly, Gilead Sciences, and P fizer outside the submitted work; has a patent lymph node specimen collection kit issued; has a patent method for collecting lymph nodes issued; is the Board Chair of Hope Foundation for Cancer Research (SouthWest Oncology Group) ; is a member of the Board of Scienti fic Advisors of the NCI; is a member of the steering committee of the National Lung Cancer Roundtable; is a participant of the sci-enti fic advisory board for the Lung Cancer Foundation of America, GO2 Foundation, Druckenmiller Center for Lung Cancer Research of the Memorial Sloan Kettering Cancer Center, and the LUNGevity Founda-tion; and is the founder of the Oncobox Devices, Inc. Dr. Lievens re-ports receiving grants or contracts from the European Union; is the chair of Health Economics of Radiation Oncology-Value Based HealthCare; and receives consulting fees from AstraZeneca. Dr. Lim reports receiving grants or contracts from AstraZeneca, Boehringer Ingelheim, Medela, Johnson and Johnson/Ethicon, Covidien/Medtronic, Guardant Health, Takeda, Lilly Oncology, and Bayer; consulting fees from Beigene, Roche, and Bristol-Myers Squibb; honorarium from Medela; has patents files outside of the scope of work; and has other financial/non financial interests outside of the scope of work. Dr. Marom reports receiving personal fees from Boehringer Ingelheim,r Merck Sharp & Dohme, and AstraZeneca outside the submitted work. Dr. Prosch reports receiving grants and contracts from Boehringer Ingelheim, AstraZeneca, and Siemens; honoraria from Boehringer Ingelheim, AstraZeneca, Siemens, Merck Sharp & Dohme, Bristol-Myers Squibb, Janssen, and Roche; and meeting support from Boehringer Ingelheim. Dr. Rusch reports receiving grants from Genelux; is a member of the Steering Committee of NIH Thoracic Malignancy; and receives non financial support from Cancer Research United Kingdom for the Mesothelioma and Radical Surgery II trial outside the submit-ted work. Dr. Opitz reports receiving institutional grants from Roche and Medtronic; is a member of the Speakers Bureau for Roche and AstraZeneca; is a member of the advisory board for AstraZeneca, Merck Sharp & Dohme, and Bristol-Myers Squibb; and has done proc-torship for Intuitive. Dr. Vasquez reports receiving grants and per-sonal fees from AstraZeneca and Roche outside of the submitted work. Dr. Van Schil reports receiving consulting fees from AstraZeneca, Roche, Bristol Myers Squibb Merck Sharp & Dohme, and Janssen; and honoraria from AstraZeneca, Roche, Bristo Myers Squibb, and Janssen outside of the submitted work. The remaining authors declare no con flict of interest.

Muestra la fuente de financiamiento declarada en la publicación.